Remarkably, our results demonstrate the efficacy of co-targeting Trx/GSH systems in GSCs using Au/L-BSO and/or PPL at IC50s within a nanomolar range, regardless of p53 status, underlining its potential as a promising therapeutic strategy in GBM. Here, TXN is linked to glioblastoma.